Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease.
OBJECTIVE
To evaluate the subfoveal choroidal thickness in Vogt-Koyanagi-Harada (VKH) disease using enhanced depth imaging optical coherence tomography.


METHODS
Retrospective observational study. Subfoveal choroidal thickness was measured using enhanced depth imaging optical coherence tomography, in which the optical coherence tomography instrument was placed close enough to the eye to obtain an inverted image, which was averaged for 100 scans. All patients were diagnosed as having the ocular findings of VKH disease with or without extraocular disorders. The patients were followed during their initial treatment with corticosteroids.


RESULTS
All 8 patients (16 eyes) with acute phase VKH disease presented with thickening of the choroid. The serous retinal detachment disappeared in 1 month after corticosteroid treatment. The mean choroidal thickness in 16 eyes decreased from 805 ± 173 μm at the first visit to 524 ± 151 μm at 3 days (P < 0.001) and 341 ± 70 μm by 2 weeks (P < 0.001).


CONCLUSIONS
Patients with active VKH disease have markedly thickened choroids, possibly related not only to inflammatory infiltration but also to increased exudation. Both the choroidal thickness and the exudative retinal detachment decreased quickly with corticosteroid treatment. Enhanced depth imaging optical coherence tomography can be used to evaluate the choroidal involvement in VKH disease in the acute stages and may prove useful in the diagnosis and management of this disease noninvasively.
Department of Ophthalmology, School of Medicine, Fukushima Medical University, Fukushima, Japan. imaruko@fmu.ac.jp
Ichiro
I
Maruko
Tomohiro
T
Iida
Yukinori
Y
Sugano
Hiroshi
H
Oyamada
Tetsuju
T
Sekiryu
Takamitsu
T
Fujiwara
Richard F
RF
Spaide
D000208:Acute Disease; D000328:Adult; D001837:Body Weights and Measures; D002829:Choroid / Q000473:pathology*; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D012163:Retinal Detachment / Q000503:physiopathology; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D014607:Uveomeningoencephalitic Syndrome / Q000188:drug therapy* / Q000503:physiopathology*
D005938:Glucocorticoids; D008775:Methylprednisolone